USPTO Patent Granted for Cognitive Disorder Treatment Compound
Summary
The USPTO has granted patent US12583884B2 to AELIS FARMA for a compound, 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one, for use in treating cognitive disorders. The patent filing date was December 18, 2019.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12583884B2 to AELIS FARMA, covering a specific pregnenolone derivative for the treatment of cognitive disorders. The patent, which has an effective grant date of March 24, 2026, details the compound 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one and its therapeutic use, noting its in vivo potency in correcting cognitive impairments.
This patent grant signifies intellectual property protection for AELIS FARMA's therapeutic compound. While not a regulatory mandate for other entities, it is a key development for the pharmaceutical sector involved in cognitive disorder treatments. Companies operating in this space should be aware of this granted patent as it may impact their own research, development, and commercialization strategies for similar compounds.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
Grant US12583884B2 Kind: B2 Mar 24, 2026
Assignee
AELIS FARMA
Inventors
Pier Vincenzo Piazza, Sandy Fabre, Stéphanie Monlezun, Mathilde Metna, Monique Vallee, Jean-Michel Revest, Daniela Cota, Giovanni Marsicano, Aline Marighetto, Andrés Ozaita, Rafael Maldonado
Abstract
The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.
CPC Classifications
C07J 7/009 A61P 25/28 A61P 25/16 A61K 31/57 A61K 31/573
Filing Date
2019-12-18
Application No.
17414826
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.